Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Prognostic relevance of a BPDCN-like immunophenotype in cytogenetically normal AML

Fabio Guolo • 11 Jun 2020
EHA 2020
Acute Myeloid Leukemia Leukemia

Fabio Guolo, MD, of the University of Genoa, Genoa, Italy, outlines the prognostic relevance of a blastic plasmacytoid dendritic cell neoplasm-like (BPDCN) immunophenotype in cytogenetically normal acute myeloid leukemia (AML) patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Fabio Guolo

Selecting patients with secondary AML for CPX-351
1:14
Selecting patients with secondary AML for CPX-351
Fabio Guolo • 13 Jun 2025
The efficacy of CPX-351 in secondary AML defined according to the WHO 2022 classification
1:15
The efficacy of CPX-351 in secondary AML defined according to the WHO 2022 classification
Fabio Guolo • 13 Jun 2025
Comparing real-world outcomes with CPX-351 versus fludarabine-based induction in secondary AML
1:19
Comparing real-world outcomes with CPX-351 versus fludarabine-based induction in secondary AML
Fabio Guolo • 6 Dec 2024
Real-world evidence of the efficacy of CPX-351 in secondary AML
1:01
Real-world evidence of the efficacy of CPX-351 in secondary AML
Fabio Guolo • 6 Dec 2024

Related Videos

How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
2:00
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
Alexey Danilov • 16 Oct 2026
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
3:39
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
Marta Coscia • 16 Oct 2026
CaDAnCe-101 trial: exploring the potential of tacabrutideg, a novel BTK degrader, in R/R CLL/SLL
4:56
CaDAnCe-101 trial: exploring the potential of tacabrutideg, a novel BTK degrader, in R/R CLL/SLL
Stephan Stilgenbauer • 16 Oct 2026
Continuous acalabrutinib versus acalabrutinib plus venetoclax in del(17p) or TP53-mutated CLL
1:22
Continuous acalabrutinib versus acalabrutinib plus venetoclax in del(17p) or TP53-mutated CLL
Marta Coscia • 16 Oct 2026
The content of VJHemOnc is intended for healthcare professionals